AlphAIalphai — Financial news for AI agents
GlobeNewswireNOV 73 min read$RLMD

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

CORAL GABLES, Fla., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Relmada Therapeutics, Inc. ( Nasdaq: RLMD, "Relmada" or the "Company" ) , a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference ...

Original reporting
GlobeNewswire · Relmada Therapeutics
Published Nov 7, 2025, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 7, 2025, 1:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$RLMDBullishMed
01

Why it matters

Earnings could act as a catalyst for stock price movement; positive results may lead to a rally, while disappointing results could cause a decline.

02

Market read

High relevance due to upcoming earnings and recent investor sentiment.

03

What to watch

Potential delays in clinical trials or regulatory setbacks could negatively impact stock performance regardless of earnings.

Timing: High, as the earnings report is scheduled for November 13, 2025.

Background

Relmada Therapeutics is a clinical-stage biotech focusing on oncology and CNS therapies, with upcoming Q3 2025 financial results.

Company-level read

Ticker impact

$RLMDBullishMedium confidence
Context

High relevance due to recent positive sentiment and upcoming earnings report.

Expected impact

Potential short-term upward movement around the earnings date, with a moderate probability (~60%) of exceeding current levels.

Evidence & confidence

The scheduled earnings report is a significant event likely to influence stock price. The current sentiment indicates investor interest, but the moderate sentiment score and lack of recent strong technical signals suggest a cautious outlook.

Market effects

Sector

Positive sentiment may boost biotech sector confidence, especially within oncology and CNS indications.

Regional

Limited regional impact; primarily affecting US biotech stocks.

Global

Moderate, as biotech sector trends can influence global markets, but specific to US-listed biotech companies.

Counterpoint

What could challenge this read

Earnings may underperform expectations, leading to a short-term decline despite positive sentiment.

Key entities

  • Company
    Relmada Therapeutics

    A biotech company specializing in innovative therapies for oncology and CNS indications.

Read at source← All news

Related articles

AUG 6
$RLMDMed

RELMADA THERAPEUTICS, INC. (RLMD): Results of Operations and Financial Condition

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030099301ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING ITS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Busin

SEC EDGAR 8-K6 min
AUG 9
$MDTMed

Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.

medicaldaily.com6 min
AUG 9
$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

dailysabah.com6 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min
AUG 9
$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

tradearabia.com3 min
AUG 9
$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

globes.co.il4 min